

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Intervet Inc.
USDA Vet Biologics Establishment Number	165A
Product Code	16J1.R2
True Name	Fowl Laryngotracheitis-Marek's Disease Vaccine, Serotypes 2 & 3, Modified Live & Live Marek's Disease Vector
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Merck Animal Health
Date of Compilation Summary	October 28, 2021

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy							
Pertaining to	Infectious Laryngotracheitis Virus							
Study Purpose	To demonstrate efficacy against infectious laryngotracheitis							
Study Furpose	virus 10 weeks after vaccination							
Product Administration	One dose administered <i>in ovo</i> at 18 days of embryonation.							
Study Animals	Specific-pathogen-free chickens divided into groups:							
	Vaccinates: 30 chickens							
	Positive Controls (10 weeks old at challenge): 10 chickens							
	Positive Controls (4 weeks old at challenge): 10 chickens							
Challenge Description	Challenged with ILT virus 10 weeks post-vaccination.							
Interval observed after	Observed for clinical signs for 10 days post-challenge.							
challenge								
Results	Summary of results:							
	Birds positive for Infectious Laryngotracheitis Disease (see raw							
	data table below for positivity criteria):							
	1 5 7							
	Vaccinates: 1/30 (3%)							
	10-week-old Controls: 7/9* (78%)							
	4-week-Old Controls: 10/10 (100%)							
	+ -week-Old Controls. 10/10 (100/0)							
	*One chicken died two days following challenge and the death							
	was determined not related to the challenge.							
	$D_{1} = 0$ (CED 112.229 = 1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1							
	Requirements per 9 CFR 113.328 were met. The 4-week-old							
	controls group validated the virulence of challenge.							
	Raw data attached							
USDA Approval Date	December 14, 2007							

Individual Bird Challenge Data

Bird ID Trea Grou	Treatment	Date:	Date:								Clinical	Necropsy	
	Group	8/17/07	8/18/07	8/19/07	8/20/07	8/21/07	8/22/07	8/23/07	8/24/07	8/25/06	8/26/07	Result (+ or -)	Result (+ or -)
2558	Vaccinate	0/1//0/	0/10/07	0/15/07	0/20/07	0/21/07	0/22/07	0/20/01	0/21/0/	0/20/00	0/20/07	-	(* 01)
2560	Vaccinate											-	
2561	Vaccinate											-	
2569	Vaccinate											-	
2572	Vaccinate											-	
2582	Vaccinate											-	
2588	Vaccinate											-	
2594	Vaccinate											-	
2599	Vaccinate											-	
2553	Vaccinate											-	
2563	Vaccinate											-	
2568	Vaccinate											_	
2586	Vaccinate											-	
2590	Vaccinate											-	
2590													
2592	Vaccinate	+	1	-	ł	-		1	-	-	ł	-	
2595	Vaccinate Vaccinate	+	ł	ł	<u> </u>			ł	ł		<u> </u>	-	
2555	Vaccinate												
											1	-	
2566	Vaccinate											-	
2574	Vaccinate										1	-	
2575	Vaccinate											-	
2587	Vaccinate										-	-	
2597	Vaccinate											-	
2601	Vaccinate											-	
2559	Vaccinate											-	
2562	Vaccinate											-	
2571	Vaccinate											-	
2576	Vaccinate											-	
2580	Vaccinate											-	
2589	Vaccinate				G	D						+	+
2668*	Placebo		D										-
2661	Placebo					G	GA					+	
2674	Placebo			G	G	D						+	+
2676	Placebo					D							+
2666	Placebo											-	
2667	Placebo			G	G	AG	AG	D				+	+
2673	Placebo											-	
2663	Placebo			G	G	G						+	
2672	Placebo				G	G						+	
2682	Placebo			G	G	G						+	
4260	Control			GA	GA	Α						+	
4264	Control			Α	GA	AG	Α					+	+
4265	Control			Α	Α	D						+	
4266	Control			GA	GA	GAO						+	
4269	Control			GA	GA	Α						+	
4270	Control			GA	GA	Α						+	
4271	Control			G	G/D							+	+
4272	Control			Α	Α	GA	D					+	+
4276	Control			GA	GA	OAG						+	
4284	Control			Α	GA	GA					Ì	+	

Clinical Signs: (D) Dead; (G) Gasping; (L) Acute Labored Breathing; (B) Expectoration of Blood; (O) Acute Ocular Discharge/Swelling and/or Sinus Swelling; (A) General Appearance, Huddled with Ruffled Feathers, Depression, and/or emaciation NOTE: If general appearance is only clinical sign, bird is considered positive if it remains morbid throughout remainder of observation and morbidity cannot be attributed to

other causes

Clinical Findings: Birds exhibiting a clinical sign for 2 or more days are considered positive (+) * Bird 2668 was not included in the final challenge results as mortality was not related to challenge.

Study Type	Efficacy					
Pertaining to	Marek's Disease Virus (MDV), Infectious Laryngotracheitis					
	Virus (ILT)					
Study Purpose	To demonstrate effectiveness against very virulent MDV and					
J	ILT.					
Product Administration	In ovo					
Study Animals	Chickens					
Challenge Description						
Interval observed after						
challenge						
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.					
USDA Approval Date	August 29, 2006					

Study Type	Safety								
Pertaining to	ALL								
Study Purpose	To demonstrate safety of product under typical field conditions								
Product	One dose was administered <i>in ovo</i> to 18-19 day old chicken embryos.								
Administration									
Study Animals	A total of 2,366,613 chickens, representing 3 distinct geographical								
	locations.								
Challenge	N/A								
Description									
Interval	Chick	Chicks were observed daily for mortality through 14 days post-hatch.							
observed after	,,,,,,,,								
challenge									
Results									
	Site	Group	Total	%	%	Condemnation			
			Placed	Hatchability	Mortality	Rates			
	1	Vaccinate	681,138	69.1-92.1	0.99-3.57	0.36-1.37			
		Control	702,801	65.5-92.1	0.93-2.36	0.65-1.15			
	2	Vaccinate	343,155	73.0-93.4	2.61-5.38*	0.37-0.47*			
		Control**		73.7-87.5					
	3	Vaccinate	1,342,320	72.9-91.3	4.50-5.17	0.78-1.12			
		Control	1,436,083	70.3-91.2	0.79-1.58	0.79-1.58			
						nly 2 has all test			
					ates were de	termined based on			
		nouses with		•					
	** Percent hatchability for Site 2 controls was the "Standard Hatch" value								
	provided by the site.								
	No adverse reactions attributable to vaccination with the test article were								
			ons attributa	able to vaccination	ion with the	test article were			
	report	reported.							
	A . 1	12 2000							
USDA	April	13, 2009							
Approval Date									